Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Bristol Gate Capital Partners Inc., managed by Richard Hamm, recently executed a significant transaction involving Eli Lilly And Company ((LLY)). The hedge fund reduced its position by 13,262 shares.
Recent Updates on Eli Lilly And Company stock
Eli Lilly (LLY) has reported multiple pipeline updates, including Phase 3 initiation of eloralintide for obstructive sleep apnea and completion of a Phase 1 obesity study of eloralintide alone and with tirzepatide, reinforcing its multi-asset metabolic strategy. The company also highlighted a completed Phase 1/2 trial of pirtobrutinib in blood cancers and new/ongoing early and late-stage cardiometabolic programs with orforglipron and LY4064809, supporting a strong long-term growth narrative though with limited immediate stock-price impact.
Spark’s Take on LLY Stock
According to Spark, TipRanks’ AI Analyst, LLY is a Outperform.
The score is driven primarily by strong profitability and upbeat 2026 guidance (large projected revenue/EPS growth and continued product/pipeline momentum). Offsetting factors are weak cash-flow metrics and high leverage, while technicals are currently bearish and valuation remains expensive with a low dividend yield.
To see Spark’s full report on LLY stock, click here.
More about Eli Lilly And Company
YTD Price Performance: -1.54%
Average Trading Volume: 3,453,070
Current Market Cap: $1000.4B